Speaking Up For Orphan Drugs
A colloquy between Sen. Orrin Hatch and HHS Secretary Nominee Tom Price offered a timely rebuttal to a strangely one-sided investigative piece on the Orphan Drug law by Kaiser Health News and NPR.
You may also be interested in...
Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.
Commissioner Gottlieb hopes accomplish through guidance a policy change that advocates failed to get included in user fee legislation passed earlier this year.
The controversy over Marathon’s pricing of the steroid deflazacort is fueling calls to revisit the US Orphan Drug Act. For Big Pharma companies, the threat should not be ignored. It is time for the industry’s biggest players to take back development of products like deflazacort to protect pricing for more innovative therapies.